Phaseline

Companies › Ribotek Biopharmaceuticals (Shandong)

Ribotek Biopharmaceuticals (Shandong): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RBD5044–Phase 2HypertriglyceridemiaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07587788RBD5044Phase 2HypertriglyceridemiaMetabolic and endocrineMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International River 3 Renal

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.